ID: MRFR/Pharma/2259-HCR | 80 Pages | Author: Kinjoll Dey | June 2023
Table of Content
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
5.7 Upcoming trends
5.7.1 Market trends
5.7.2 Technological trends
5.7.3 Insurance & Regulations
5.7.4 Others
6. Global Intravenous Immunoglobulin (IVIg) Market by Type
6.1 IgA
6.1.1 IgA1
6.1.2 IgA2
6.2 IgD
6.3 IgE
6.4 IgG
6.5 IgM
7. Global Intravenous Immunoglobulin (IVIg) Market by Application
7.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
7.1.1 Progressive
7.1.2 Recurrent
7.1.3 Monophasic
7.2 Hypogammaglobulinemia
7.2.1 AGM1
7.2.2 AGM2
7.2.3 AGM3
7.2.4 AGM4
7.2.5 AGM5
7.2.6 AGM6
7.3 Multifocal Motor Neuropathy
7.4 Immunodeficiency diseases
7.4.1 X-linked agammaglobulinemia (XLA)
7.4.2 Common variable immunodeficiency (CVID)
7.2.4 Severe combined immunodeficiency
7.5 Primary Humoral Immunodeficiency
7.5.1 B cell (antibody) deficiencie
7.5.2 T cell deficiencies
7.5.3 Combination BT cell deficiencies
7.5.4 Defective phagocytes
7.5.5 Complement deficiencies
7.5.6 Unknown (idiopathic)
7.6 Myasthenia Gravis
7.6.1 Generalized myasthenia gravis
7.6.2 Ocular myasthenia gravis
7.6.3 Congenital myasthenia gravis
7.6.4 Transient neonatal myasthenia gravis
7.7 Guillain-Barre syndrome
7.7.1 Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
7.7.2 Miller Fisher syndrome (MFS)
7.7.3 Acute motor axonal neuropathy (AMAN)
7.7.4 Acute motor-sensory axonal neuropathy (AMSAN)
7.8 Kawasaki disease
7.9 ITP
7.9.1 Acute
7.9.2 Chronic
7.9 Others
8. Global Intravenous Immunoglobulin (IVIg) Market by Region
8.1 Introduction
8.2 America
8.2.1 North America
8.2.1.1 The US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.3 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 South Korea
8.4.5 Rest of Asia
8.5 Pacific
8.6 Middle East and Africa
8.6.1 UAE
8.6.2 Saudi Arabia
8.6.3 Egypt
8.6.4 Rest of Middle East and Africa
9 Conclusion
9.1 Key findings
9.1.1 From CEO’s viewpoint
9.1.2 Unmet needs of the market
9.2 Key companies to watch
9.3 Prediction of medical robots industry
10 Appendix
Market Segmentation
Intravenous Immunoglobulin (IVIg) Type Outlook (USD Billion, 2019-2030)
IgD
IgG
IgE
IgA
IgM
Intravenous Immunoglobulin (IVIg) Application Outlook (USD Billion, 2019-2030)
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Intravenous Immunoglobulin (IVIg) Regional Outlook (USD Billion, 2019-2030)
North America Outlook (USD Billion, 2019-2030)
North America Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
North America Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
US Outlook (USD Billion, 2019-2030)
US Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
US Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
CANADA Outlook (USD Billion, 2019-2030)
CANADA Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
CANADA Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Europe Outlook (USD Billion, 2019-2030)
Europe Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Europe Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Germany Outlook (USD Billion, 2019-2030)
Germany Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Germany Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
France Outlook (USD Billion, 2019-2030)
France Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
France Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
UK Outlook (USD Billion, 2019-2030)
UK Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
UK Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
ITALY Outlook (USD Billion, 2019-2030)
ITALY Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
ITALY Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Spain Outlook (USD Billion, 2019-2030)
Spain Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Spain Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Rest of Europe Outlook (USD Billion, 2019-2030)
Rest of Europe Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Rest of Europe Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Asia Pacific Outlook (USD Billion, 2019-2030)
Asia Pacific Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Asia Pacific Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
China Outlook (USD Billion, 2019-2030)
China Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
China Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Japan Outlook (USD Billion, 2019-2030)
Japan Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Japan Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
India Outlook (USD Billion, 2019-2030)
India Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
India Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Australia Outlook (USD Billion, 2019-2030)
Australia Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Australia Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Rest of Asia Pacific Outlook (USD Billion, 2019-2030)
Rest of Asia Pacific Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Rest of Asia Pacific Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Rest of World Outlook (USD Billion, 2019-2030)
Rest of World Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Rest of World Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Middle East Outlook (USD Billion, 2019-2030)
Middle East Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Middle East Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Africa Outlook (USD Billion, 2019-2030)
Africa Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Africa Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy
Latin America Outlook (USD Billion, 2019-2030)
Latin America Intravenous Immunoglobulin (IVIg) by Type
IgD
IgG
IgE
IgA
IgM
Latin America Intravenous Immunoglobulin (IVIg) by Application
Guillain–Barré Syndrome
Hypogammaglobulinemia
Specific Antibody Deficiency
Chronic Inflammatory Polyneuropathy
Inflammatory Myopathies
Myasthenia Gravis
Idiopathic Thrombocytopenic Purpura
Multifocal Motor Neuropathy